<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5048381 Figure_1-C</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) 293T cells were transfected with empty vector (EV), a vector encoding FLAG-tagged full length CYLD (wt), or constructs encoding FLAG-tagged CYLD fragments 1-581 (F1) lacking the C-terminus, or 581-956 (F2) lacking the N-terminus, as indicated, followed by FLAG-IP. The blot was probed with antibodies recognizing SPATA2, FLAG and tubulin. Endogenous SPATA2 was co-immunoprecipitated to comparable levels by CYLD and the C-terminal CYLD protein fragment, containing the USP domain.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_1-D</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) CYLD-/- MEF were infected with retrovirus encoding FLAG-CYLD as indicated and CYLD was purified by FLAG-IP. The blot was probed with antibodies recognizing CYLD, SPATA2 and actin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_1-E</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) 293T cells were transfected with empty vector (EV), a vector encoding FLAG-tagged full length SPATA2 or a construct encoding the FLAG-tagged N-terminal part of SPATA2 (NT), as indicated, followed by FLAG-IP. The blot was probed with antibodies recognizing CYLD, SPATA2 and tubulin. M, marker lane.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_2-A</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) 293T cells were transfected with a vector encoding V5-tagged full length SPATA2, along with empty vector (EV) a vector encoding FLAG-tagged HOIP wild-type (wt) or a vector encoding a FLAG-tagged PUB domain mutant of HOIP (N102A). After FLAG-IP, the blot was probed with antibodies recognizing HOIP, CYLD, V5 and actin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_2-B</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 2-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) 293T cells were transfected with empty vector or a vector encoding FLAG-tagged HOIP along with either V5-tagged SPATA2 (wt) or a V5-tagged PIM mutant (PIMmut) of SPATA2. After V5-IP, the blot was probed with antibodies recognizing FLAG, CYLD, V5 and tubulin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_2-C</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 2-C</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) 293T cells were transfected with a vector encoding FLAG-tagged HOIP and increasing amounts of V5-tagged SPATA2. After FLAG-IP, the blot was sequentially probed with antibodies recognizing OTULIN, HOIP, V5 and tubulin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_2-D</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 2-D</infon>
    <infon key="sourcedata_figure_dir">Figure_2-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) 293T cells were transfected with empty vector, FLAG-SPATA2 or FLAG-HOIP. After FLAG-IP, the blot was probed with antibodies recognizing OTULIN, CYLD, FLAG and actin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_2-E</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 2-E</infon>
    <infon key="sourcedata_figure_dir">Figure_2-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) 293T cells were transfected with empty vector, V5-tagged SPATA2 (wt) or a V5-tagged PUB domain mutant PUBmut of SPATA2. After V5-IP, the blot was probed with antibodies recognizing CYLD, FLAG, V5 and tubulin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_2-F</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 2-F</infon>
    <infon key="sourcedata_figure_dir">Figure_2-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) A549 cells were treated with FLAG-TNF (2&#181;g/ml) for the indicated time. The purified TNF-RSC was sequentially probed with antibodies recognizing SPATA2, CYLD, RIPK1, TRADD, SHARPIN, TNF and tubulin as indicated.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_3-A</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) A549 cells were infected to express a CRISPR/Cas9 system targeting luciferase (as control, indicated wt) or the spata2 gene (ko). Mixed cell cultures were treated with FLAG-huTNF (2&#181;g/ml) for the indicated time. The purified TNF-RSC was sequentially probed with antibodies recognizing SPATA2, CYLD, HOIP, SHARPIN, TRADD, TNF and tubulin as indicated.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_3-B</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) MEF were infected to express a CRISPR/Cas9 system targeting luciferase (wt) or the spata2 gene (ko). Single clones were generated, which were treated with FLAG-TNF (2&#181;g/ml) for the indicated time. The purified TNF-RSC was sequentially probed with antibodies recognizing M1-linked ubiquitin, CYLD, RIPK1, and tubulin as indicated.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_4-A-B-C</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 4-A-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>FLAG-tagged CYLD or catalytically inactive FLAG-CYLD (C598A), respectively, were stably expressed in CYLD-/-MEF, followed by infection with control retrovirus, or retrovirus encoding SPATA2, and purified by FLAG-IP. Purified CYLD or the inactive mutant were added to recombinant di-ubiquitin for 0, 20 or 40 min at 37&#176;C as indicated. After electrophoresis, the gel was cut and the lower part was silver stained to visualize mono-and di-ubiquitin, while the upper part was transferred to a membrane and probed for FLAG and V5. In (A), the experiment was done with M1-linked di-ubiquitin substrate, in (B) K63-linked di-ubiquitin substrate was subjected to the assay, and in (C) K48-linked di-ubiquitin substrate was analyzed.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_5-A</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) MEF expressing CRISPR/Cas9 targeting luciferase (wt) or single clones generated from MEF expressing CRISPR/Cas9 targeting the spata2 gene (ko) were treated with mTNF (10 ng/ml) as indicated. The blots were probed with antibodies recognizing P-IkB&#945; IkB&#945;, P-p38, p38, P-JNK, JNK, P-p65, p65 and tubulin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_5-B</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 5-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) 15P-1 Sertoli cells expressing CRISPR/Cas9 targeting luciferase (as control) or single clones generated from 15P-1 Sertoli cells expressing CRISPR/Cas9 targeting the spata2 gene were treated with mTNF (10 ng/ml) as indicated. The blots were probed with antibodies recognizing P-IkB&#945;, IkB&#945;, P-p38, p38, P-JNK, JNK, P-p65, p65 and tubulin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_5-C</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) TAK1-/-MEF were infected to express a CRISPR/Cas9 system targeting luciferase or the spata2 gene, from which single clones were generated. The cells were treated with mTNF (10 ng/ml) or mTNF along with Necrostatin-1 (Nec-1) for 1-3 h as indicated. The blot was sequentially probed with antibodies recognizing PARP, cleaved caspase-3 and tubulin.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_5-D</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D). The same cells as used in (C) were treated as before with TNF (10 ng/ml) or TNF along with Necrostatin-1 (Nec-1) for one and 2 h as indicated. Caspase activity was determined using the fluorogenic substrate DEVD-AMC.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_5-E</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 5-E</infon>
    <infon key="sourcedata_figure_dir">Figure_5-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) Cells from the experiment as shown in (D) were analyzed for apoptosis by Annexin V staining after 2 h. In (D) and (E), a representative experiment is shown with error bars referring to technical replicates.</text>
    </passage>
  </document>
  <document>
    <id>5048381 Figure_5-F</id>
    <infon key="sourcedata_document">2146</infon>
    <infon key="doi">10.15252/embr.201642592</infon>
    <infon key="pmc_id">5048381</infon>
    <infon key="figure">Figure 5-F</infon>
    <infon key="sourcedata_figure_dir">Figure_5-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) Cells as described before were treated with mTNF (10 ng/ml) for the indicated time and lysates were subjected to immunoprecipitation with an anti-FADD antibody. The immunoprecipitates were subjected to Western blotting and probed for RIPK1, FADD and actin.</text>
    </passage>
  </document>
</collection>
